Poor performance status (PS) is an indication for an aggressive approach to neoadjuvant chemotherapy in patients with advanced epithelial ovarian cancer (EOC)

Gynecologic Oncology
Heike SeifertSusana Banerjee

Abstract

Some guidelines suggest that poor performance status (PS) is a contraindication to 1st line chemotherapy. Poor PS is a known adverse prognostic factor in advanced epithelial ovarian cancer (EOC). We show in this retrospective analysis that 1st line chemotherapy in this patient group is not only safe but is associated with good outcomes. A retrospective review of 114 patients with stage III/IV EOC, who presented with a PS ≥3 at diagnosis and treated as inpatients with upfront platinum-based chemotherapy between 2000 and 2013, at the Royal Marsden Hospital, was conducted. The association between clinical parameters and the likelihood of completion of chemotherapy and overall survival (OS) was assessed. 66% of patients completed ≥6cycles of platinum-based chemotherapy. Prognostic factors for completion of chemotherapy were improvement of PS during hospital stay (p<0.001) and doublet-chemotherapy with carboplatin/paclitaxel compared to single-agent carboplatin (p=0.004). A negative trend for completion of treatment was seen for patients with low albumin (<25g/l) and low CA125 levels at baseline. The median OS for all patients was 13.1months (95% CI: 10.4-15.8) and 21.2months (95% CI: 16.5-25.8) for those who completed 6cycles of ch...Continue Reading

References

Oct 1, 1994·British Journal of Obstetrics and Gynaecology·D ParkerJ J Price
Jul 16, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert F OzolsUNKNOWN Gynecologic Oncology Group
May 26, 2007·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·A Poveda VelascoUNKNOWN GEICO Group
Aug 21, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·William E WinterUNKNOWN Gynecologic Oncology Group Study
Sep 8, 2010·The New England Journal of Medicine·Ignace VergoteUNKNOWN NCIC Clinical Trials Group
Feb 18, 2011·Current Opinion in Supportive and Palliative Care·Desiree F Kolomainen, Desmond P J Barton
Apr 12, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Lowell E SchnipperDana S Wollins
Sep 3, 2014·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Algirdas MarkauskasPernille Tine Jensen

❮ Previous
Next ❯

Citations

Mar 25, 2018·International Journal of Clinical Oncology·Hisamitsu TakayaNoriomi Matsumura

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Incidence & Mortality

Cancer has emerged as a global concern due to its increase in incidence and mortality. Efforts are underway to evaluate and develop action plans to reduce the global burden of cancer. Currently, lung cancer, breast cancer and prostate cancer are the leading causes of cancer mortality. Here is the latest research on cancer incidence and mortality.